FDA’s Final Risk-Benefit Guidance Excludes 510(k)s, Adds De Novo Petitions
This article was originally published in The Gray Sheet
Executive Summary
Device center reviewers will begin applying the guidance to incoming PMA and de novo submissions and to submissions already under review with decisions beginning on May 1.